Clinical Trials Logo
  1. Home
  2. Calciphylaxis
  3. NCT04195906

Phase 3 Study of SNF472 for Calciphylaxis — Calciphyx  

Calciphylaxis Clinical Trial

Official title:
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of SNF472 When Added to Background Care for the Treatment of Calciphylaxis

Clinical Trial Summary

The primary objectives are to assess the efficacy, safety, and tolerability of SNF472 compared to placebo when added to background care for the treatment of calciphylaxis (CUA).

Clinical Trial Description

The formation and growth of calcified deposits in arterioles and other small blood vessels appears to be fundamental to the development of CUA especially in end stage renal disease patients. This phase 3 double-blind, randomized, placebo-controlled study is designed to assess the effect of SNF472 when added to background care to improve wound healing, as evaluated using Bates-Jensen Wound Assessment Tool (BWAT) scoring and pain as reported by the subject using a VAS scale. The study consists of a double-blind, randomized, placebo controlled period of 12 weeks followed by an open-label period of 12 weeks.. . ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04195906
Study type Interventional
Source Sanifit Therapeutics S. A.
Contact
Status Completed
Phase Phase 3
Start date February 12, 2020
Completion date October 24, 2022
View Details
See also
  Status Clinical Trial Phase
Completed NCT01578382 - Pathophysiology of Martorell Hypertensive Ischemic Leg Ulcer (HYTILU)
Active, not recruiting NCT04592640 - Stem Cells for Uremic Calciphylaxis Patients N/A
Terminated NCT03319914 - Observational Follow-up to ST-001 Calciphylaxis Pain Treatment With Intravenous Sodium Thiosulfate
Recruiting NCT06065852 - National Registry of Rare Kidney Diseases
Terminated NCT03150420 - A Phase 3 Clinical Trial of Intravenous Sodium Thiosulfate in Acute Calciphylaxis Patients Phase 3
Completed NCT02790073 - Phase 2 Study With SNF472 in Calciphylaxis Patients Phase 2
Recruiting NCT03146793 - The Early Administration of Sodium Thiosulfate Should Help to Reduce the Mortality of Dialysis Patients With Calciphylaxis, From a National Cohort N/A
Completed NCT02278692 - Evaluation of Vitamin K Supplementation for Calcific Uremic Arteriolopathy N/A
Completed NCT02854046 - Calciphylaxis : Population, Risk Factors, Diagnostic Practice, Therapeutic and Outcome
Terminated NCT02527213 - Randomized Double Blind Placebo Controlled Trial of Sodium Thiosulfate for the Treatment of Pain Associated With Calcific Uremic Arteriolopath Phase 3
Recruiting NCT03032835 - Partners Calciphylaxis Biobank
Completed NCT01289626 - Efficacy of Lanthanum Carbonate in Calciphylaxis Phase 1
Recruiting NCT06283589 - The SEAPORT 1 Study: Evaluation of the Safety and Tolerability of INZ-701 in Adults With End-Stage Kidney Disease Undergoing Hemodialysis Phase 1
Recruiting NCT02635373 - European Calciphylaxis Registry Network N/A
Recruiting NCT05018221 - Better Evidence and Translation for Calciphylaxis Phase 3